Zobrazeno 1 - 10
of 43
pro vyhledávání: '"David P. Rosenbaum"'
Autor:
Anthony J. Lembo, Susan Edelstein, David P. Rosenbaum, Ceciel Rooker, Jeffrey D. Roberts, William D. Chey
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Summary This document provides a short summary of the T3MPO-3 study, which was published in Neurogastroenterology and Motility in September 2023. At the end of this summary, there are links to websites where you can find more information about this s
Externí odkaz:
https://doaj.org/article/a42748ddee794bc48998e93ed4093048
Publikováno v:
Acta Psychologica, Vol 241, Iss , Pp 104089- (2023)
Effective handling of objects requires proper use of the hands. If the object handling is done while standing or walking, it also requires proper use of the feet. We asked how people position their feet to meet future and ongoing object-handling dema
Externí odkaz:
https://doaj.org/article/d42068144a0f4bf6981fdc66377d0621
Autor:
Csaba P. Kovesdy, David P. Rosenbaum, Jeffrey W. Jacobs, Adebowale Adebiyi, L. Darryl Quarles
Publikováno v:
International Journal of Nephrology and Renovascular Disease
Plasma membrane sodium–hydrogen exchangers (NHE) transport Na+ into cells in exchange for H+. While there are nine isoforms of NHE in humans, this review focuses on the NHE3 isoform, which is abundantly expressed in the gastrointestinal tract, wher
Autor:
Yang Yang, Daniel E. Weiner, Robert I. Lynn, Anthony J. Bleyer, Arnold L. Silva, Glenn M. Chertow, Geoffrey A. Block, David P. Rosenbaum
Publikováno v:
Kidney360
BACKGROUND: Treating hyperphosphatemia is a tenet of dialysis care. This trial assessed the safety and efficacy of tenapanor for the management of hyperphosphatemia. METHODS: In this 52-week phase 3 study (NCT03427125), participants receiving mainten
Publikováno v:
J Am Soc Nephrol
BACKGROUND: Hyperphosphatemia is associated with cardiovascular morbidity and mortality in patients receiving maintenance dialysis. It is unknown whether combining two therapies with different mechanisms of action—tenapanor, an inhibitor of paracel
Publikováno v:
The American Journal of Gastroenterology
INTRODUCTION: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the tre
Publikováno v:
The American Journal of Gastroenterology
OBJECTIVES: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of pa
Autor:
Lucinda A. Harris, David P. Rosenbaum
Publikováno v:
American Journal of Gastroenterology. 117:e393-e393
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Tenapanor, a first-in-class, phosphate absorption inhibitor blocks the paracellular absorption of phosphate in the GI tract by local inhibition of the sodium-hydrogen exchanger (NHE3). It therefore provides a novel, non-binder app
Publikováno v:
Gastroenterology. 162:S-756